HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please email our help desk at Readiness Help

Prime Recipient Report

Award Detail for: DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE
Recipient Name:MT SINAI SCHOOL OF MEDICINE
DUNS Number: 078861598
1 GUSTAVE L LEVY PL, BOX 3500
NEW YORK-NEW YORK, NY 10029-6500

Reporting Information

Award Type*: Grant

Award Number*: 5RC1AI086061-02

Final Report*: Recipient responsible for this data

Award Recipient Information

Recipient DUNS Number*: 078861598

Recipient Account Number: Recipient responsible for this data

Recipient Congressional District*: 15

Award Information

Funding Agency Code*: 7529

Awarding Agency Code*:7529

Award Date*: 08-24-2010

Amount of Award*: $ 500,000

Program Source (TAS)*: 750845

CFDA Number*: 93.701

Sub Account Number for Program Source (TAS)*: Recipient responsible for this data

Total Number of Sub Awards to Individuals*: Recipient responsible for this data

Total Amount of Sub Awards to Individuals*: Recipient responsible for this data

Total Number of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Amount of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Number of Sub Awards less than $25,000/award*: Recipient responsible for this data

Total Amount of Sub Awards less than $25,000/award*: Recipient responsible for this data

Award Description* DESCRIPTION (provided by applicant): This application addresses broad challenge area (15) Translational Science and specific Challenge Topic, 15-AI-106: translational research focused on high priority pathogens and basic research focused on resistance mechanisms. The research described herein can be initiated immediately and completed within two years. The work proposed will maintain or create three full time positions and will require the purchase of products and services from the biotech industry. In the longer term, the outcome of the proposed research may stimulate the economy by greatly reducing employee absenteeism due to influenza illness and eliciting the investment of vaccine companies in the optimization and manufacture of universal influenza vaccines. Specifically, we propose the development of novel influenza vaccine constructs which have the potential to protect against a wide range of antigenically-drifted variant viruses and against multiple subtypes influenza A viruses. The design of these constructs is based on our and others' recent observations that monoclonal antibodies which bind to the conserved stalk region of the influenza A virus hemagglutinin (HA) molecule are both broadly cross-reactive and neutralizing. The identified epitope is highly conformational, comprising portions of both the HA1 and HA2 subunits, and is located in the membrane proximal region of the HA protein. During natural infection or vaccination with conventional influenza vaccines, this region of the HA molecule is thought to be masked by the membrane distal portion of HA, a bulky and highly immunogenic globular head domain. Indeed, the immune response to vaccines currently in use is predominantly targeted against the globular head of HA; since this domain is very poorly conserved, current vaccines protect only against relatively small clusters of closely related strains. We have identified a way of expressing a modified HA molecule which lacks the globular head domain and maintains the structural integrity of the stalk region. This molecule forms the basis for a new generation of influenza vaccines which will induce broadly cross- neutralizing antibodies against the conserved stalk region. Such vaccines have the potential to provide protection against epidemic strains arising over several decades, obviating the need for annual influenza vaccination. In addition, vaccines based on the conserved HA stalk domain are predicted to be effective against influenza viruses of most (perhaps all) of the 16 HA subtypes and therefore to provide protection in the event of an influenza pandemic. PUBLIC HEALTH RELEVANCE: The research we propose is aimed at developing a new influenza virus vaccine which has the potential to protect against many distinct types of influenza virus. If successful, this vaccine could protect recipients against influenza for decades, rather than for just one or two years as the current vaccines do. In addition, since it would work against a broad range of influenza viruses, it would provide protection in the event of an influenza pandemic.

Project Information

Project Name or Project/Program Title*: DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE

Project Status*: Recipient responsible for this data

Total Federal Amount of ARRA Funds Received/Invoiced*: Recipient responsible for this data

Number of Jobs*: Recipient responsible for this data

Description of Jobs Created*: Recipient responsible for this data

Quarterly Activities/Project Description*: Recipient responsible for this data

Activity Code (NAICS or NTEE-NPC)*: Recipient responsible for this data

Total Federal Amount of ARRA Expenditure* (Enter the cumulative total amount of Recovery Funds received that were expended to projects or activities. Refer to the Data Model for details on how to calculate this amount.): Recipient responsible for this data

Total Federal ARRA Infrastructure Expenditure Recipient responsible for this data

Infrastructure Contact Name: Recipient responsible for this data

Infrastructure Contact Email: Recipient responsible for this data

Infrastructure Contact Phone: Recipient responsible for this data

Infrastructure Contact Phone Ext: Recipient responsible for this data

Infrastructure Contact Street Address 1: 1 GUSTAVE L LEVY PL, BOX 3500

Infrastructure Contact Street Address 2: Not Available

Infrastructure Contact Street Address 3: Recipient responsible for this data

Infrastructure City: NEW YORK-NEW YORK

Infrastructure State: NY

Infrastructure ZIP Code+4: 10029-6500

Infrastructure Purpose and Rationale (If applicable, enter an explanation about how the infrastructure investment will contribute to one or more purposes of the Recovery Act. Refer to the Data Model for details on what to report. 4000 characters or less.): Recipient responsible for this data

Primary Place of Performance

Street Address 1: BOX 1075

Street Address 2: NEW YORK

City*: NEW YORK

State*: NY

ZIP Code+4*: 10029

Congressional District*: 14

Country*: US

Recipient Highly Compensated Officers

Prime Recipient Indication of Reporting Applicability*: Recipient responsible for this data

1. Officer Name and Compensation: Recipient responsible for this data
2. Officer Name and Compensation: Recipient responsible for this data
3. Officer Name and Compensation: Recipient responsible for this data
4. Officer Name and Compensation: Recipient responsible for this data
5. Officer Name and Compensation: Recipient responsible for this data

This concludes the current search. To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool Landing Page.